Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -16431.82% is 56256% below its 5-year average of 29.26%, near the low end of its 5-year range (-16431.82%–100.00%).
969.42% below its 12-month average of -1536.52%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3823.53%.
GROSS MARGIN
-16431.82%
GROSS MARGIN AVG TTM
-1536.52%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
29.26%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-969.42%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-56255.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-39809.57%
vs the sector median at left
Senti Biosciences, Inc.
Market Cap
$10.30M
Gross Margin
-16431.82%
TTM Avg
-1536.52%
3Y Avg
0.00%
5Y Avg
29.26%
Market Cap
$10.39M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$10.41M
Gross Margin
N/A
TTM Avg
-101.19%
3Y Avg
-33.23%
5Y Avg
-22.16%
Market Cap
$10.18M
Gross Margin
0.00%
TTM Avg
44.31%
3Y Avg
60.00%
5Y Avg
55.54%
Market Cap
$10.10M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Senti Biosciences, Inc. (SNTI) | $10.30M | -16431.82% | -1536.52% | 0.00% | 29.26% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.39M | 0.00% | 0.00% | 0.00% | 0.00% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.41M | N/A | -101.19% | -33.23% | -22.16% |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.18M | 0.00% | 44.31% | 60.00% | 55.54% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.10M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lifeward Ltd. (LFWD)vs › | $10.10M | 35.95% | 35.13% | 34.24% | 39.24% |
| Polyrizon Ltd. (PLRZ)vs › | $10.58M | N/A | 0.00% | 0.00% | 0.00% |
| Pluri Inc. (PLUR)vs › | $10.69M | 44.59% | 46.77% | 72.29% | -10.14% |
| MetaVia Inc. (MTVA)vs › | $9.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Valion Bio, Inc. (VBIO)vs › | $9.82M | 0.00% | 0.00% | 10.16% | 1.65% |
Gross Margin
-16431.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -3823.53% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | -3959.09% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | -29.24% |
| 2023-03-31 | 27.76% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 8.51% |
| 2021-12-31 | -30.39% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | -20.68% |
| 2021-03-31 | -6709.72% |
| 2020-12-31 | -177700.00% |
